Carolus Therapeutics Gets $2.25M In Debt Funding

San Diego-based Carolus Therapeutics, a developer of biopharmaceuticals aimed at treating acute and chronic inflammation, has scored $2.25M in a debt funding round, according to financing provider Square 1 Bank. According to Square 1, the new funding will go support future growth at Carolus. Carolus Therapeutics is venture backed by Avalon Ventures, and is headed by Court Turner, who is both CEO of Carolus and a venture partner at Avalon. The firm's biopharmaceuticals are aimed at respiratory diseases such as cystic fibrosis. Terms of the debt funding were not announced by the companies.